Due Diligence (IP & Patents)

Licensing and acquisition decisions carry technical, regulatory and intellectual-property risk that headline data rarely reveals — and the gap between an asset's pitch and its real condition is where deals go wrong. PharmExpert provides due diligence spanning technical and regulatory condition and IP/patent position, so deal teams decide on evidence rather than optimism.

On the technical and regulatory side we assess CMC and manufacturing, quality-system and compliance history, regulatory status and the quality of the dossier and data — surfacing the issues that determine whether the asset can actually deliver what the deal assumes.

On the IP side we assess the patent landscape, freedom-to-operate and exclusivity considerations, coordinating with IP counsel where needed, because a strong product with a weak patent position is a very different proposition.

We quantify the risks and the remediation effort and cost, then give a clear-eyed verdict that deal teams can act on — and that can inform valuation. Speed matched to deal timelines, with rigor concentrated on the highest-risk areas.